Evolving clinical profile of IL-1β, IL-10 and CTLA-4 gene in rheumatoid factor positive Caucasian population

Anupama Sharma, Ajay kumar Singh, Sanjeev kumar Singh, Neelima Singh, Varsha Gupta, Int J Cur Bio Med Sci. (2011) Evolving clinical profile of IL-1β, IL-10 and CTLA-4 gene in rheumatoid factor positive Caucasian population. [Journal (Paginated)]

Full text available as:

PDF (Evolving clinical profile of IL-1β, IL-10 and CTLA-4 gene in rheumatoid factor positive Caucasian population ) - Published Version
Available under License Creative Commons Attribution No Derivatives.



Rheumatoid arthritis (RA), a systemic autoimmune condition, causes joint damage and sometimes extra-articular lesions (cutaneous vasculitis, neuropathy, Felty’s syndrome, pericarditis, intersticial lung disease) that may be life threatening. The reason why extra-articular features will develop in rare RA patients is unknown. Our study was aimed to find any disease correlation with respect to a few genetic loci implicated in rheumatoid arthritis. In our study no significant association was observed for Il-1β and IL-10. However CTLA-4 showed polymorphism in RA and controls. In our earlier article we reported polymorphism of HLA-DRB1 in Caucasian population. The study was conducted on 60 patients, where 30 were control and 30 were diseased. All the patients selected for the study were Rf (rheumatoid factor) positive. Therefore the studies need to be conducted on larger group of patients, so that the association can be verified in Caucasian population (Indian scenario).

Item Type:Journal (Paginated)
Keywords:rheumatoid arthritis, Rheumatoid factor, Caucasian population, CTLA-4, IL-10, IL-1
ID Code:7316
Deposited By: CurrentSciDirect Publications, International Journal of Current Biological and Medical Science (IJCBMS)
Deposited On:02 May 2011 15:52
Last Modified:02 May 2011 15:52

References in Article

Select the SEEK icon to attempt to find the referenced article. If it does not appear to be in cogprints you will be forwarded to the paracite service. Poorly formated references will probably not work.

[1] Feldmann M, Brennan F M, Maini R N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996; 14:397–440.

[2] Simon AK, Seipelt E, Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci USA . 1994; (18): 8562–8566.

[3] Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996; 85(3):307–310.

[4] AlnaeeliM,Penninger JM,TengYT. Immuneinteractions withCD4_T cellspromote the development of functional osteoclasts from murine CD11c_dendritic cells. J Immunol. 2006;177(5):3314–3326.

[5] McInnes IB, SchettG. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev. 2007; 7(6):429–442.

[6] Bresnihan B, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum.1998; 41(12):2196–2204.

[7] Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 2002; 46(12):3143– 3150.

[8] Talwalkar SC, Grennan DM, Gray J, Johnson P, Hayton MJ. Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis. 2005; 64(4):650–651.

[9] Goldbach-Mansky R, Lipsky PE. New concepts in the treatment of rheumatoid arthritis. Annu Rev Med. 2003; 54:197–216.

[10] Vincenti F, Luggen M. T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. Annu Rev Med. 2007; 58:347– 358.

[11] Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity. 1997; 7(4):445–450.

[12] Hueber AJ, et al. CTLA-4 lacking the cytoplasmic domain costimulates IL-2 production in T-cell hybridomas. Immunol Cell Biol. 2006; 84(1):51–58.

[13] Ling V, Wu PW, Finnerty HF, Sharpe AH, Gray GS, Collins M. Complete sequence determination of the mouse and human CTLA4 gene loci: cross-species DNA sequence similarity beyond exon borders. Genomics. 1999; 60(3):341–355.

[14] Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ, Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomilehto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Rønningen KS, Guja C, Ionescu-Tîrgovişte C, Savage DA, Maxwell AP, Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB, Wicker LS, Todd JA, Gough SC. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature. 2003; 423(6939):506–511.

[15] Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol. 2006; 24:65–97.

[16] Rudd CE. The reverse stop-signal model for CTLA4 function. Nat Rev. 2008; 8(2):153–160.

[17] Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, Straus D, Samelson LE, Thompson CB, Bluestone JA. Molecular basis of T cell inactivation by CTLA-4. Science. 1998; 282(5397):2263–2266.

[18] Schneider H, daRocha Dias S, HuH RuddCE. Aregulatory role for cytoplasmicYVKM motif in CTLA-4 inhibition of TCR signaling. Eur J Immunol. 2001; 31(7): 2042–2050.

[19] Lei AT, Liw, Liew A, Bombardier C, Weisman M, Massarotti EM, Kent J, Wolfe F, Begovich AB, Gregersen PK. The PTPN22R620W polymorphism associates with RF+ rheumatoid arthritis in a dose dependent manner but not with HLA-SE status. Genes Immun. 2005; 6:129-133.

[20] Barton A, Myerscough A, John S, Gonzalez-Gay M, Ollier W, Worthington J. A single nucleotide polymorphism in exon 1 of Cytotoxic T-lymphocyte-associated-4 (CTLA-4) is not associated with rheumatoid arthritis. Rheumatology. 2000; 39:63–66.

[21] Milicic A, Brown MA, Wordsworth BP. Polymorphism in codon 17 of the CTLA-4 gene (+49 A/G) is not associated with susceptibility to rheumatoid arthritis in British Caucasians. Tissue Antigens. 2001; 58:50–54.

[22] Lee YH, Choi SJ, Ji JD, Song GG. No association of polymorphisms of the CTLA-4 exon 1(+49) and promoter (-318) genes with rheumatoid arthritis in the Korean population. Scand J Rheumatol . 2002; 31:266–270.

[23] Lee CS, Lee YJ, Liu HF, Su CH, Chang SC, Wang BR, Chen TL, Liu TL. Association of CTLA4 gene A-G polymorphism with rheumatoid arthritis in Chinese. Clin Rheumatol. 2003; 22:221–224.

[24] Seidl C, Donner H, Fischer B, Usadel KH, Seifried E, Kaltwasser JP, Badenhoop K. CTLA4 codon 17 dimorphism in patients with rheumatoid arthritis. Tissue Antigens.. 1998; 51:62–66.

[25] Yanagawa T, Gomi K, Nakao EI, Inada S. CTLA-4 gene polymorphism in Japanese patients with rheumatoid arthritis. J Rheumatol. 2000; 27:2740–2742.

[26] Vaidya B, Pearce SHS, Charlton S, Marshall N, Rowan AD, Griggiths ID, Kendall-Taylor P, Cascuston TE ,Young-Min S. An association between the CTLA-4 exon1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. J Rheumatol. 2002; 41:180-183.

[27] Arend WP, Gabay C. Physiologic role of interleukin-1receptor antagonist. Arthritis Res. 2000; 2: 245-8.

[28] Mottonen M, Isomaki P, Saario R, Toivanen P, Punnonen, J,Lassila O. Interleukin-10 inhibits the capacity of synovial macrophages to function as antigen-presenting cells. Br J Rheumatol. 1998; 37: 1207-14.

[29] G A Mittal, VR Joshi. IL –10 In early rheumatoid arthritis, J Indian Rheumatol Assoc. 2002; 10 : 59 – 60.

[30] Katsikis PD, Chu CQ Brennan FM, Maini RN, Feldmann M. Immunoregulatory role of interleukin-10 in rheumatoid arthritis. J Exp Med. 1994;179: 1527-34.

[31] Jorgensen C, Apparilly, F, Sany J. Review. Immunological evaluation of cytokine and anti-cytokine immunotherapy in vivo: what have we learnt? Ann Rheum Dis. 1999; 58:136-41.


Repository Staff Only: item control page